{
    "nct_id": "NCT06465953",
    "official_title": "A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)",
    "inclusion_criteria": "* Diagnosis of HMA naive IDH1 R132 mutated MDS defined according to WHO criteria (5th edition):\n* Moderate high, high and very high-risk MDS per IPSS-M score will be eligible regardless of blood counts and with blast counts 0-19%.\n* Low and moderate low-risk MDS per IPSS-M score must:\n* Have cytopenias related to MDS, defined as: <100 platelets/microliter, or absolute neutrophil count (ANC) <1000/mm3, or hemoglobin <10g/dL AND\n* Have a blast count between 5-19% AND\n* Be eligible for HMA therapy (very low risk participants are to be excluded)\n* Locally or centrally confirmed IDH1 R132 C/G/H/L/S mutation\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received prior anticancer/disease modifying treatment for MDS (including HMA's, cytotoxic chemotherapy, investigational agents, bcl-2 inhibitor based-regimens, hematopoietic stem cell transplant (HSCT), IDH1 inhibitors). For LR-MDS patients, prior treatment with growth factors, luspatercept, lenalidomide, and imetelstat are allowed.\n* >20% blasts by morphology or immunohistochemistry on screening bone marrow aspirate/biopsy",
    "miscellaneous_criteria": ""
}